Chronic administration of an aglycosylated murine antibody of ponezumab does not worsen microhemorrhages in aged Tg2576 mice

Current Alzheimer Research

Volumn 9, Issue 9, 2012, Pages 1059-1068

  Freeman, Gary B ^a   Brown, Thomas P ^a   Wallace, Karin ^a   Bales, Kelly R ^a  

^a PFIZER INC   (United States)

Author keywords

A ; CAA; Microhemorrhage; Murine surrogate; Ponezumab (PF 04360365); Safety; Tg2576 mice

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; EOSIN; HEMATOXYLIN; PONEZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN HEMORRHAGE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EXPOSURE; FEMALE; FOOD INTAKE; HISTOPATHOLOGY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; TOXICITY TESTING; TOXICOKINETICS; TREATMENT DURATION;

AGING; ALZHEIMER DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN EDEMA; CEREBRAL HEMORRHAGE; DISEASE MODELS, ANIMAL; FEMALE; MICE; MICE, TRANSGENIC;

EID: 84870162666     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512803569064     Document Type: Article

References (52)

1. Selkoe DJ. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3: 75-80 (2001).
2. Agostinho P, Cunha RA, Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr Pharm Des 16: 2766-2778 (2010).
3. Alberdi E, Sanchez-Gomez MV, Cavaliere F, Perez-Samartin A, Zugaza JL, Trullas R, et al. Amyloid β oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 47: 264-272 (2010).
4. Jang MH, Piao XL, Kim HY, Cho EJ, Baek SH, Kwon SW, et al. Resveratrol oligomers from Vitis amurensis attenuate β-amyloidinduced oxidative stress in PC12 cells. Biol Pharm Bull 30:1130-1134 (2007).
5. Small DH, Gasperini R, Vincent AJ, Hung AC, Foa L. The role of Aβ-induced calcium dysregulation in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 16: 225-233 (2009).
6. Veerhuis R, Boshuizen RS, Familian A. Amyloid associated proteins in Alzheimer's and prion disease. Curr Drug Targets CNS Neurol Disord 4: 235-248 (2005).
7. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185 (1992).
8. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356 (2002).
9. Wong CW, Quaranta V, Glenner GG. Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. Proc Natl Acad Sci USA 82: 8729-8732 (1985).
10. Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke 18: 311-324 (1987).
11. Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y. High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy. Am J Pathol 145: 452-460 (1994).
12. Alonzo NC, Hyman BT, Rebeck GW, Greenberg SM. Progression of cerebral amyloid angiopathy: accumulation of amyloid-beta40 in affected vessels. J Neuropathol Exp Neurol 57: 353-359 (1998).
13. McCarron MO, Nicoll JA, Stewart J, Cole GM, Yang F, Ironside JW, et al. Amyloid-beta protein length and cerebral amyloid angiopathy-related haemorrhage. Neuro Report 11: 937-940 (2000).
14. Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 109: 813-836 (2002).
15. Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, et al. Human apolipoprotein E4 alters the amyloid beta 40:42 ratio and promotes formation of cerebral angiopathy in an amyloid precursor protein transgenic model. J Neurosci 25: 2803-2810 (2005).
16. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, et al. Exacerbation of cerebral amyloid angiopathyassociated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β. J Neurosci 25: 629-636 (2005).
17. Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, et al. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 26: 5340-5346 (2006).
18. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298:1379 (2002).
19. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24: 6144-6151. (2004).
20. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes par enchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1: 24 (2004).
21. Wilcock DM, Colton CA. Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets 8: 50-64 (2009).
22. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer's disease. Neurology 73: 2061-2070 (2009).
23. Fryer JD, Taylor JW, DeMattos RB, Bales KR, Paul SM, Parsadanian M, et al. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J Neurosci 23: 7889-7896 (2003).
24. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 7: 954-960 (2004)
25. Thakker DR, Weatherspoon MR, Harrison J, Keene TE, Lane DS, Kaemmerer WF, et al. Intracerebroventricular amyloid-β antibodies reduce cerebral amyloid angiopathy and associated microhemorrhages in aged Tg2576 mice. Proc Natl Acad Sci USA 106: 4501-4506 (2009).
26. Sperling RA, Jack CR, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimer's & Dementia 7: 367-385 (2011).
27. LaPorte SL, Bollini SS, Lanz TA, Abdiche YN, Rusnak AS, Ho WH, et al. Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of alzheimer's disease. J Mol Biol 421(4-5): 525-536 (2012).
28. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98: 8850-8855 (2001).
29. Gelinas DS, DaSilva K, Fenili D, St George-Hyslop P, McLaurin J. Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci USA 101(2):14657-14662 (2004).
30. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21: 372-381 (2001).
31. Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, et al. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem 276: 12991-12998 (2001).
32. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102. (1996).
33. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94: 13287-13292 (1997).
34. Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, Wiederhold KH, et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci USA 96: 14088-14093 (1999)
35. Armour KL, van de Winkel JGJ, Williamson LM, Clark MR. Differential binding to human FcγRIIa and FcγRIIb receptors by human IgG wildtype and mutant antibodies. Mol Immunol 40: 585-593 (2003).
36. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER). Guidance for industry: M3 Nonclinical safety studies for the conduct of human clinical trials for pharmaceuticals. http://ocw.jhsph.edu/courses/drugdevelopment/PDFs/FDA_Guidance_on_Nonclinical_Safety_Studies.pdf
37. Lanz TA, Schachter JB. Solid-phase extraction enhances detection of beta-amyloid peptides in plasma and enables Aβ quantification following passive immunization with Aβ antibodies. J Neurosci Methods 169: 16-22 (2008).
38. Draper NR, Hunter WG. Transformations: some examples revisited. Technometrics 11: 23-40. (1969).
39. Levene H. Robust tests for equality of variances. In (Eds: Olkin I, Ghurye SG, Hoeffding W, Madow WG, and Mann HB). Contributions to Probability and Statistics: Essays in Honor of Harold Hotelling. Stanford: Stanford University Press pp. 278-292 (1960).
40. Winer BJ. Statistical principles in experimental design, 2nd ed. New York: McGraw-Hill Book Company (1971).
41. Dunnett CW. A multiple comparisons procedure for comparing several treatments with a control. J Am Stat Assoc 50: 1096-1121 (1955).
42. Dunnett CW. New tables for multiple comparisons with a control. Biometrics 20: 482-491 (1964).
43. Welch BL. The generalisation of "Student's" problems when several different population variances are involved. Biometrika 34: 28-35 (1947).
44. Haseman JK, Elwell MR, Hailey JR. Neoplasm incidences in B6C3F1 mice: NTP historical data. In: Pathology of the Mouse, ed. RR Maronpot, 679-689 (1999).
45. Karlnoski RA, Rosenthal A, Alamed J, Ronan V, Gordon MN, Gottschall PE, et al. Deglycosylated anti-Aβ antibody doseresponse effects on pathology and memory in APP transgenic mice. J Neuroimmune Pharmacol 3: 187-197 (2008).
46. Burbach GJ, Vlachos A, Ghebremedhin E, Del Turco D, Coomaraswamy J, Staufenbiel M, et al. Vessel ultrastructure in APP23 transgenic mice after passive anti-Abeta immunotherapy and subsequent intracerebral hemorrhage. Neurobiol Aging 28: 202-212 (2007).
47. Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN. Amyloidbeta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 144: 950-960 (2007).
48. Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T, et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci 28: 6787-6793 (2008).
49. Armour KL, Atherton A, Williamson LM, Clark MR. The contrasting IgG-binding interactions of human and herpes simplex virus Fc receptors. Biochem Soc Trans 30: 495-500 (2002).
50. Carty NC, Wilcock DM, Rosenthal A, Grimm J, Pons J, Ronan V, et al. Intracranial administration of deglycosylated C-terminalspecific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. J Neuroinflammation 3: 11 (2006).
51. Freeman GB, Lin JC, Pons J, Raha NM. 39-week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomolgus monkeys with 12-week recovery period. J Alzheimers Dis 28: 531-541 (2012).
52. Meyer-Luehmann M, Mora JR, Mielke M, Spires-Jones TL, de Calignon A, von Andrian UH, et al. T cell mediated cerebral hemorrhages and microhemorrhages during passive Aβ immunization in APPPS1 transgenic mice. Mol Neurodegener 6: 22 (2011).